Table 1.
Compound | Status |
|
NanoBRET GAK IC50 (nM) | Reference | Kinome | Other targets | |||
---|---|---|---|---|---|---|---|---|---|
AAK1 | BIKE | GAK | STK16 | ||||||
(5Z)-7- Oxozeaenol | Investigational | 13%*** | 3.8%*** | 10%*** | 100%*** | NA | Pu et al.,2020 | ID: 20211 | TAK1 (8 nM), VEGFR2 (52 nM), ERK2 (80 nM) |
Sunitinib | Approved (cancer) | 11 nM* | 5.5 nM* | 20 nM* | 250 nM* | NA | Davis et al.,2011 | Davis et al.,2011 | VEGFR2 (80 nM), PDGFRβ (2 nM), FLT3, KIT, PDGFRα |
Erlotinib | Approved (cancer) | 1200 nM* | 1200 nM* | 3 nM* | >9000 nM* | 910 nM | Asquith et al., 2019a, Asquith et al., 2019b | Davis et al.,2011 | ErbB1 (0.7 nM), STK10 (19 nM), YSK4 (25 nM), SLK (26 nM) |
Gefitinib | Approved (cancer) | >10,000 nM**a | >10,000 nM**a | 13 nM* | NA | 420 nM | Asquith et al., 2019a, Asquith et al., 2019b | Davis et al.,2011 | EGFR |
Baricitinib | Approved (RA) | 17 nM* | 40 nM* | 134 nM∗ | 69 nM* | NA | Stebbing et al.,2021 | Klaeger et al.,2017 | JAK1 (5.9 nM), JAK2 (5.7 nM), ROCK1/2, TYK2 (53 nM), CAMK2A, MAP3K2, PRPF4B |
RMC-76 | Experimental | 4 nM** | 3.8 nM*a | 280 nM*a | NA | NA | Figure S1 | NA | CDC42BPB, PRKD3, CLK1, CLK4, ULK3, MINK1 |
RMC-242 | Experimental | 4100 nM*a | >15000 n M*a | 12 nM** | NA | 78 nMa | Martinez-Gualda et al.,2021 | NA | NA |
SGC-GAK-1 | Experimental | NA 86%*** |
NA 92%*** |
2 nM* 9.7%*** |
NA 84%*** |
48 nM | Asquith et al., 2019a, Asquith et al., 2019b | Asquith et al., 2019a, Asquith et al., 2019b | RIPK2 (110 nM), ADCK3 (190 nM), NLK (520 nM) |
STK-16-1N-1 | Experimental | NA 13%*** |
NA 9.5%*** |
NA 46%*** |
295 nM** 0.65%*** |
NA | Liu et al., 2016 | Liu et al.,2016 | PI3Kδ (856 nM), PI3Kγ (867 nM) |
Data obtained in this study, RA= Rheumatoid Arthritis